GLAND PHARMA LIMITED

Scale -

Ebitda is 1946 Rs Cr; Annual Growth is 31 %
PBT is 435 Rs Cr; Annual Growth is 38 %
PAT is 1027 Rs Cr; Annual Growth is 47 %
Quarterly Revenue is 1800 Rs Cr; Continuous Growth over 3 Quarters

Profitability -

PBDIT Margin is 30.25 %; Annual Growth is 15 %
PAT Margin is 15.97 %; Annual Growth is 28 %; 5 Year CAGR is -13 %

Return -

ROCE is 13.96 %; Annual Growth is 22 %
ROA is 8.21 %; Annual Growth is 32 %
ROE is 9.91 %; Annual Growth is 30 %; in Bottom Quartile

Asset Turnover is 54 %; in Bottom Quartile

Efficiency -

Current Ratio is 4.68; Continuous Growth over 3 years; in Top Quartile
Quick Ratio is 3.6; Continuous Growth over 3 years; in Top Quartile
Inventory Turnover Ratio is 3.75; Continuous Growth over 3 years; 5 Year CAGR is 23 %

Solvancy -

Debt/Equity is 0.02; Annual Decline is -33 %; Continuous Decline over 3 years
Long term Debt is 69.93 Rs Cr; Continuous Decline over 3 years; 5 Year CAGR is 107 %
Total Debt is 243 Rs Cr; Continuous Decline over 3 years; 5 Year CAGR is 181 %

Contingent Liabilities is 433 Rs Cr; Annual Growth is 135 %; Continuous Growth over 3 years; 5 Year CAGR is 37 %

Quality -

Change in Inventories/Total Expenses is 0 %; Annual Decline is -103 %; Continuous Decline over 3 years
Other Expenses/Total Expenses is 14 %; in Bottom Quartile

Operating cashflow/PAT is 100 %; Annual Decline is -23 %
Operating cashflow/ebitda is 53 %; Continuous Decline over 3 years
Current Tax/PAT is 45 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector

Major Subsidiaries/Associates

Key Clients

Products

Products

Product details

Operations

Capacity/ Production

Key Facilities

Key Certifications

Raw materials

Search: